CervoMed Inc. - Common Stock (CRVO)

The company is now poised to initiate late-stage trials for Neflamapimod.

CervoMed reports 32-week data showing neflamapimod slowed DLB progression and reduced neurodegeneration biomarkers with good tolerability.

Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

A look at the top 20 most-searched stocks on Benzinga Pro in March. While many had news in the month that could affect rankings, the trends could be a sign of what's to come.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.

On Monday, there are stocks with unusual volume. Let's take a look.

Let's have a look at what is happening on the US markets on Friday. Below you can find the stocks with an unusual volume in today's session.

Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session.

CervoMed's Phase 2b study extension shows improved cognitive outcomes with neflamapimod, leading to an analyst upgrade and increased confidence in the drug.

Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.

Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.

Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.